Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 1NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 46Neoplasms 36Colorectal Neoplasms 36Lung Neoplasms 21Breast Neoplasms 13Colonic Polyps 11Colonic Neoplasms 11Rare Diseases 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 7Pulmonary Disease, Chronic Obstructive 6Neoplasm Metastasis 6Heart Failure 6Ovarian Neoplasms 5Motor Activity 5Liver Neoplasms 5Head and Neck Neoplasms 5Fibrosis 5Carcinoma, Squamous Cell 5Barrett Esophagus 5Adenoma 5Urinary Bladder Neoplasms 4Neoplasms by Site 4Mental Disorders 4Lymphoma 4Lung Diseases 4Leukemia 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Urinary Incontinence 3

Interventions

Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Interventional × Respiratory Distress Syndrome × Clear all
NCT00029328 2015-03-25

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

FDA Office of Orphan Products Development

Phase 1/2 Completed
15 enrolled

Bronchiolitis Obliterans, Pneumonia, Respiratory Distress Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡